SLFN11 and metastatic neoplasm: Another study examined the patient-derived xenografts (PDXs) response to DDA and has shown SLFN11 is significantly elevated in metastatic tumors compared to non-metastatic ones, and high SLFN11 metastatic PDXs showed better response to therapy with DNA damaging agents [94].